vs
Fair Isaac（FICO）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是Fair Isaac的1.1倍（$540.7M vs $512.0M），Fair Isaac净利率更高（30.9% vs -2.9%，领先33.8%），Fair Isaac同比增速更快（16.4% vs -14.1%），Fair Isaac自由现金流更多（$173.9M vs $36.0M），过去两年Fair Isaac的营收复合增速更高（8.6% vs -2.3%）
FICO（原Fair, Isaac and Company）是美国知名数据分析企业，1956年由比尔·费尔与厄尔·艾萨克创立，总部位于蒙大拿州博兹曼市，核心业务为信用评分服务，其推出的FICO信用分是评估消费者信贷风险的重要指标，目前已被美国消费信贷行业广泛采用。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
FICO vs ICUI — 直观对比
营收规模更大
ICUI
是对方的1.1倍
$512.0M
营收增速更快
FICO
高出30.5%
-14.1%
净利率更高
FICO
高出33.8%
-2.9%
自由现金流更多
FICO
多$137.9M
$36.0M
两年增速更快
FICO
近两年复合增速
-2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $512.0M | $540.7M |
| 净利润 | $158.4M | $-15.7M |
| 毛利率 | 83.0% | 37.5% |
| 营业利润率 | 45.7% | 1.0% |
| 净利率 | 30.9% | -2.9% |
| 营收同比 | 16.4% | -14.1% |
| 净利润同比 | 3.8% | 34.0% |
| 每股收益（稀释后） | $6.61 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FICOICUI
| Q4 25 | $512.0M | $540.7M | ||
| Q3 25 | $515.8M | $537.0M | ||
| Q2 25 | $536.4M | $548.9M | ||
| Q1 25 | $498.7M | $604.7M | ||
| Q4 24 | $440.0M | $629.8M | ||
| Q3 24 | $453.8M | $589.1M | ||
| Q2 24 | $447.8M | $596.5M | ||
| Q1 24 | $433.8M | $566.7M |
净利润FICOICUI
| Q4 25 | $158.4M | $-15.7M | ||
| Q3 25 | $155.0M | $-3.4M | ||
| Q2 25 | $181.8M | $35.3M | ||
| Q1 25 | $162.6M | $-15.5M | ||
| Q4 24 | $152.5M | $-23.8M | ||
| Q3 24 | $135.7M | $-33.0M | ||
| Q2 24 | $126.3M | $-21.4M | ||
| Q1 24 | $129.8M | $-39.5M |
毛利率FICOICUI
| Q4 25 | 83.0% | 37.5% | ||
| Q3 25 | 82.3% | 37.4% | ||
| Q2 25 | 83.7% | 37.9% | ||
| Q1 25 | 82.4% | 34.7% | ||
| Q4 24 | 80.1% | 36.1% | ||
| Q3 24 | 80.3% | 34.8% | ||
| Q2 24 | 80.3% | 34.8% | ||
| Q1 24 | 80.0% | 32.7% |
营业利润率FICOICUI
| Q4 25 | 45.7% | 1.0% | ||
| Q3 25 | 46.0% | 2.6% | ||
| Q2 25 | 48.9% | 1.9% | ||
| Q1 25 | 49.3% | 2.1% | ||
| Q4 24 | 40.8% | 6.0% | ||
| Q3 24 | 43.4% | 1.4% | ||
| Q2 24 | 42.5% | 1.3% | ||
| Q1 24 | 44.9% | -1.9% |
净利率FICOICUI
| Q4 25 | 30.9% | -2.9% | ||
| Q3 25 | 30.1% | -0.6% | ||
| Q2 25 | 33.9% | 6.4% | ||
| Q1 25 | 32.6% | -2.6% | ||
| Q4 24 | 34.7% | -3.8% | ||
| Q3 24 | 29.9% | -5.6% | ||
| Q2 24 | 28.2% | -3.6% | ||
| Q1 24 | 29.9% | -7.0% |
每股收益（稀释后）FICOICUI
| Q4 25 | $6.61 | $-0.63 | ||
| Q3 25 | $6.41 | $-0.14 | ||
| Q2 25 | $7.40 | $1.43 | ||
| Q1 25 | $6.59 | $-0.63 | ||
| Q4 24 | $6.14 | $-0.97 | ||
| Q3 24 | $5.44 | $-1.35 | ||
| Q2 24 | $5.05 | $-0.88 | ||
| Q1 24 | $5.16 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $162.0M | — |
| 总债务越低越好 | $3.2B | — |
| 股东权益账面价值 | $-1.8B | $2.1B |
| 总资产 | $1.9B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FICOICUI
| Q4 25 | $162.0M | — | ||
| Q3 25 | $134.1M | — | ||
| Q2 25 | $189.0M | — | ||
| Q1 25 | $146.6M | — | ||
| Q4 24 | $184.3M | $308.6M | ||
| Q3 24 | $150.7M | $312.5M | ||
| Q2 24 | $156.0M | $302.6M | ||
| Q1 24 | $135.7M | $251.4M |
总债务FICOICUI
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $2.0B | — |
股东权益FICOICUI
| Q4 25 | $-1.8B | $2.1B | ||
| Q3 25 | $-1.7B | $2.1B | ||
| Q2 25 | $-1.4B | $2.1B | ||
| Q1 25 | $-1.1B | $2.0B | ||
| Q4 24 | $-1.1B | $2.0B | ||
| Q3 24 | $-962.7M | $2.0B | ||
| Q2 24 | $-829.3M | $2.0B | ||
| Q1 24 | $-735.7M | $2.1B |
总资产FICOICUI
| Q4 25 | $1.9B | $4.1B | ||
| Q3 25 | $1.9B | $4.1B | ||
| Q2 25 | $1.9B | $4.1B | ||
| Q1 25 | $1.8B | $4.2B | ||
| Q4 24 | $1.7B | $4.2B | ||
| Q3 24 | $1.7B | $4.3B | ||
| Q2 24 | $1.7B | $4.3B | ||
| Q1 24 | $1.7B | $4.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $174.1M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $173.9M | $36.0M |
| 自由现金流率自由现金流/营收 | 34.0% | 6.6% |
| 资本支出强度资本支出/营收 | 0.0% | 4.6% |
| 现金转化率经营现金流/净利润 | 1.10× | — |
| 过去12个月自由现金流最近4个季度 | $750.6M | $91.8M |
8季度趋势，按日历期对齐
经营现金流FICOICUI
| Q4 25 | $174.1M | $60.6M | ||
| Q3 25 | $223.7M | $56.7M | ||
| Q2 25 | $286.2M | $11.2M | ||
| Q1 25 | $74.9M | $51.3M | ||
| Q4 24 | $194.0M | $40.2M | ||
| Q3 24 | $226.5M | $36.1M | ||
| Q2 24 | $213.3M | $82.0M | ||
| Q1 24 | $71.0M | $45.8M |
自由现金流FICOICUI
| Q4 25 | $173.9M | $36.0M | ||
| Q3 25 | $219.5M | $27.6M | ||
| Q2 25 | $284.4M | $-8.5M | ||
| Q1 25 | $72.8M | $36.7M | ||
| Q4 24 | $193.2M | $16.1M | ||
| Q3 24 | $224.7M | $16.2M | ||
| Q2 24 | $211.6M | $62.5M | ||
| Q1 24 | $67.0M | $29.9M |
自由现金流率FICOICUI
| Q4 25 | 34.0% | 6.6% | ||
| Q3 25 | 42.6% | 5.1% | ||
| Q2 25 | 53.0% | -1.5% | ||
| Q1 25 | 14.6% | 6.1% | ||
| Q4 24 | 43.9% | 2.6% | ||
| Q3 24 | 49.5% | 2.7% | ||
| Q2 24 | 47.2% | 10.5% | ||
| Q1 24 | 15.4% | 5.3% |
资本支出强度FICOICUI
| Q4 25 | 0.0% | 4.6% | ||
| Q3 25 | 0.8% | 5.4% | ||
| Q2 25 | 0.3% | 3.6% | ||
| Q1 25 | 0.4% | 2.4% | ||
| Q4 24 | 0.2% | 3.8% | ||
| Q3 24 | 0.4% | 3.4% | ||
| Q2 24 | 0.4% | 3.3% | ||
| Q1 24 | 0.9% | 2.8% |
现金转化率FICOICUI
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.57× | 0.32× | ||
| Q1 25 | 0.46× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.67× | — | ||
| Q2 24 | 1.69× | — | ||
| Q1 24 | 0.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FICO
| Business To Business Scores | $248.6M | 49% |
| Saa S Products | $115.7M | 23% |
| Platform Software | $73.9M | 14% |
| Business To Consumer Scores | $55.9M | 11% |
| Technology Service | $19.2M | 4% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
